Total Payments
$274,886
2024 Payments
$3,600
Companies
14
Transactions
180
Payment Breakdown by Category
Consulting$204,839 (74.5%)
Travel$36,294 (13.2%)
Research$21,631 (7.9%)
Other$7,453 (2.7%)
Food & Beverage$4,670 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $204,839 | 69 | 74.5% |
| Travel and Lodging | $36,294 | 44 | 13.2% |
| Unspecified | $21,631 | 3 | 7.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,453 | 8 | 2.7% |
| Food and Beverage | $4,670 | 56 | 1.7% |
Payments by Type
General
$253,256
177 transactions
Research
$21,631
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $56,059 | 17 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $52,593 | 25 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $43,824 | 21 | $0 (2019) |
| Novartis Pharma AG | $24,576 | 9 | $0 (2018) |
| Daiichi Sankyo Inc. | $20,463 | 18 | $0 (2019) |
| Medtronic Vascular, Inc. | $19,745 | 47 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $15,350 | 7 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $14,140 | 5 | $0 (2021) |
| Boehringer Ingelheim International GmbH | $8,044 | 10 | $0 (2021) |
| Janssen Research & Development, LLC | $5,738 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,600 | 2 | Janssen Research & Development, LLC ($3,600) |
| 2023 | $2,138 | 2 | Janssen Research & Development, LLC ($2,138) |
| 2022 | $14,700 | 3 | E.R. Squibb & Sons, L.L.C. ($7,400) |
| 2021 | $21,888 | 7 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($8,100) |
| 2020 | $41,580 | 16 | E.R. Squibb & Sons, L.L.C. ($19,757) |
| 2019 | $20,444 | 14 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($6,100) |
| 2018 | $55,974 | 64 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,880) |
| 2017 | $114,563 | 72 | Boehringer Ingelheim Pharmaceuticals, Inc. ($27,094) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 03/08/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 06/27/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 01/31/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 12/14/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $6,900.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/14/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| 01/10/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2021 | Boehringer Ingelheim International GmbH | PRADAXA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,288.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/16/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 07/06/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 05/13/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $4,300.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/11/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PSYCHIATRY | ||||||
| 02/11/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: PSYCHIATRY | ||||||
| 01/21/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 12/10/2020 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| 12/10/2020 | Boehringer Ingelheim International GmbH | PRADAXA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,146.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/10/2020 | Boehringer Ingelheim International GmbH | PRADAXA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,932.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/13/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| 09/22/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,675.00 | General |
| 06/18/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 06/12/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| 06/11/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: PSYCHIATRY | ||||||
| 05/05/2020 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 04/24/2020 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $20,265 | 1 |
| DIAGNOSE AF | Medtronic Vascular, Inc. | $1,366 | 2 |
About Dr. J Easton, MD
Dr. J Easton, MD is a Neurology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043254329.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. J Easton, MD has received a total of $274,886 in payments from pharmaceutical and medical device companies, with $3,600 received in 2024. These payments were reported across 180 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($204,839).
Ad
Practice Information
- Specialty Neurology
- Location Providence, RI
- Active Since 06/16/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1043254329
Products in Payments
- REXULTI (Drug) $29,187
- BREXPIPRAZOLE (Drug) $26,856
- PRADAXA (Drug) $20,796
- FTY (Drug) $14,739
- Gilenya (Drug) $6,687
- SB6523 (Drug) $6,200
- DS1040 (Drug) $5,883
- Repatha (Biological) $5,188
- PLAVIX (Drug) $4,611
- FTY720I (Drug) $3,150
- Reveal LINQ (Device) $1,955
- Enhertu (Drug) $1,260
- AMPYRA (Drug) $1,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Providence
Syed Rizvi, Md, MD
Neurology — Payments: $482,996
Neurology $482,996
Stephen Salloway, Md, MD
Neurology — Payments: $323,920
Neurology $323,920
Jeffrey Wishik, Md, MD
Neurology — Payments: $46,542
Neurology $46,542
Dr. Karen Furie, Md, MD
Neurology — Payments: $31,250
Neurology $31,250
Dr. Chuang-Kuo Wu, M.d., Phd, M.D., PHD
Neurology — Payments: $27,531
Neurology $27,531
Joseph Friedman, Md, MD
Neurology — Payments: $18,203
Neurology $18,203